PRPH
ProPhase Labs, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.05
P/S
0.36
EV/EBITDA
-0.31
DCF Value
$-12.72
FCF Yield
-5828.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
191.4%
Operating Margin
-2496.6%
Net Margin
-3872.2%
ROE
-404.4%
ROA
-63.5%
ROIC
-156.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $883.0K | $-6.8M | $-1.60 |
| Q2 2025 | $1.2M | $-4.5M | $-1.10 |
| Q1 2025 | $1.4M | $4.0M | $2.10 |
| Q4 2024 | $-2.5M | $-34.4M | $-15.80 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.32
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.